Patrick D. Lamy

1.7k total citations
15 papers, 1.4k citations indexed

About

Patrick D. Lamy is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Patrick D. Lamy has authored 15 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 11 papers in Virology and 4 papers in Epidemiology. Recurrent topics in Patrick D. Lamy's work include HIV/AIDS drug development and treatment (13 papers), HIV Research and Treatment (11 papers) and HIV/AIDS Research and Interventions (11 papers). Patrick D. Lamy is often cited by papers focused on HIV/AIDS drug development and treatment (13 papers), HIV Research and Treatment (11 papers) and HIV/AIDS Research and Interventions (11 papers). Patrick D. Lamy collaborates with scholars based in United States, Canada and United Kingdom. Patrick D. Lamy's co-authors include Julie M. Cherrington, Andrew Mulato, Michael D. Miller, Alison D. Murray, Kenneth Hirsch, Eric M. Yoshida, Robert Perrillo, Klaus S. Gutfreund, Teresa L. Wright and Eugene R. Schiff and has published in prestigious journals such as Hepatology, Journal of Virology and The Journal of Infectious Diseases.

In The Last Decade

Patrick D. Lamy

15 papers receiving 1.3k citations

Peers

Patrick D. Lamy

ID

VIROL

EPIDE

HEPAT

MB

Stéphanie Dominguez France

Jean‐Pierre Allain United Kingdom

Cynthia Wat United Kingdom

Laurence Morand‐Joubert France

Maria Franca Pirillo Italy

Jean‐Claude Schmit Luxembourg

Herve Momméja-Marin United States

Helen Devereux United Kingdom

David Rey France

Winai Ratanasuwan Thailand

Stéphanie Dominguez France

Patrick D. Lamy

590 ×0.6

ID

370 ×0.5

VIROL

553 ×0.8

EPIDE

518 ×1.1

HEPAT

39 ×0.4

MB

Citations per year, relative to Patrick D. Lamy Patrick D. Lamy (= 1×) peers Stéphanie Dominguez

Countries citing papers authored by Patrick D. Lamy

Since Specialization

Citations

This map shows the geographic impact of Patrick D. Lamy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick D. Lamy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick D. Lamy more than expected).

Fields of papers citing papers by Patrick D. Lamy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick D. Lamy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick D. Lamy. The network helps show where Patrick D. Lamy may publish in the future.

Co-authorship network of co-authors of Patrick D. Lamy

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick D. Lamy. A scholar is included among the top collaborators of Patrick D. Lamy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick D. Lamy. Patrick D. Lamy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

1.

Louie, Michael J., Christine Hogan, Arlene Hurley, et al.. (2003). Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS. 17(8). 1151–1156. 69 indexed citations

2.

Miller, Michael D., Nicolas Margot, Patrick D. Lamy, et al.. (2001). Adefovir and Tenofovir Susceptibilities of HIV-1 After 24 to 48 Weeks of Adefovir Dipivoxil Therapy: Genotypic and Phenotypic Analyses of Study GS-96-408. JAIDS Journal of Acquired Immune Deficiency Syndromes. 27(5). 450–458. 26 indexed citations

3.

Barditch‐Crovo, Patricia, Steven G. Deeks, Sharon Safrin, et al.. (2001). Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults. Antimicrobial Agents and Chemotherapy. 45(10). 2733–2739. 268 indexed citations

4.

Miller, Michael D., Nicolas Margot, Patrick D. Lamy, et al.. (2001). Adefovir and Tenofovir Susceptibilities of HIV-1 After 24 to 48 Weeks of Adefovir Dipivoxil Therapy: Genotypic and Phenotypic Analyses of Study GS-96-408. JAIDS Journal of Acquired Immune Deficiency Syndromes. 27(5). 450–458. 3 indexed citations

5.

Perrillo, Robert, Eugene R. Schiff, Eric M. Yoshida, et al.. (2000). Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology. 32(1). 129–134. 341 indexed citations

6.

Miller, Michael D., et al.. (1999). Human Immunodeficiency Virus Type 1 Expressing the Lamivudine‐Associated M184V Mutation in Reverse Transcriptase Shows Increased Susceptibility to Adefovir and Decreased Replication Capability In Vitro. The Journal of Infectious Diseases. 179(1). 92–100. 117 indexed citations

7.

Howard, Todd K., et al.. (1999). FULMINANT HEPATIC FAILURE RESULTING FROM LAMIVUDINE-RESISTANT HEPATITIS B VIRUS IN A RENAL TRANSPLANT RECIPIENT. Transplantation. 68(12). 1912–1914. 86 indexed citations

8.

Rompay, Koen K. A. Van, Peter J. Dailey, Ross P. Tarara, et al.. (1999). Early Short-Term 9-[2-( R )-(Phosphonomethoxy)Propyl]Adenine Treatment Favorably Alters the Subsequent Disease Course in Simian Immunodeficiency Virus-Infected Newborn Rhesus Macaques. Journal of Virology. 73(4). 2947–2955. 48 indexed citations

9.

Wainberg, Mark A., Michael D. Miller, Yudong Quan, et al.. (1999). In vitro Selection and Characterization of HIV-1 with Reduced Susceptibility to PMPA. Antiviral Therapy. 4(2). 87–94. 205 indexed citations

10.

Rompay, Koen K. A. Van, Julie M. Cherrington, Marta L. Marthas, et al.. (1999). 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) Therapy Prolongs Survival of Infant Macaques Inoculated with Simian Immunodeficiency Virus with Reduced Susceptibility to PMPA. Antimicrobial Agents and Chemotherapy. 43(4). 802–812. 35 indexed citations

11.

Bowen, E Frances, Julie M. Cherrington, Patrick D. Lamy, et al.. (1999). Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy. Journal of Medical Virology. 58(4). 402–407. 13 indexed citations

12.

Cherrington, Julie M., Michael D. Fuller, Patrick D. Lamy, et al.. (1998). In Vitro Antiviral Susceptibilities of Isolates from Cytomegalovirus Retinitis Patients Receiving First‐ or Second‐Line Cidofovir Therapy: Relationship to Clinical Outcome. The Journal of Infectious Diseases. 178(6). 1821–1825. 30 indexed citations

13.

Miller, Michael D., Patrick D. Lamy, Michael D. Fuller, et al.. (1998). Human Immunodeficiency Virus Type 1 Reverse Transcriptase Expressing the K70E Mutation Exhibits a Decrease in Specific Activity and Processivity. Molecular Pharmacology. 54(2). 291–297. 22 indexed citations

14.

Mulato, Andrew, et al.. (1998). Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from AIDS Patients after Prolonged Adefovir Dipivoxil Therapy. Antimicrobial Agents and Chemotherapy. 42(7). 1620–1628. 34 indexed citations

15.

Deeks, Steven G., Ann C. Collier, Jacob Lalezari, et al.. (1997). The Safety and Efficacy of Adefovir Dipivoxil, a Novel Anti‐Human Immunodeficiency Virus (HIV) Therapy, in HIV‐Infected Adults: A Randomized, Double‐Blind, Placebo‐Controlled Trial. The Journal of Infectious Diseases. 176(6). 1517–1523. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact